Source: International Congress 2015 – Lung cancer therapy: clinical trials
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Ying-ying Gu (Guangzhou, China), Juhong Jiang, Yingying Gu. Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy. Eur Respir J 2015; 46: Suppl. 59, 4841

Member's Comments

No comment yet.

Related content which might interest you: Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Noninvasive detection of EGFR T790M mutation in gefitinib resistant non-small cell lung cancer using mutant-enriched PCR Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013 EGFR frequency and response to chemotherapy in a Brazilian NSCLC population Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 EGFR mutations determine EGFR-MET crosstalk and MET inhibition in lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 High pretreatment plasma VEGF level is associated with shorter survival in paclitaxel-carboplatin treated non-small cell lung carcinoma patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014